Seeking Alpha -- Bristol-Myers Squibb (BMY) and Eli Lilly (LLY) announced Thursday that they had settled their dispute over rights to necitumumab, formerly known as IMC-11F8, an antibody which must rank as one of the most squabbled over in recent times.
